Efficacy and Safety of Oral PCSK9 Inhibitors in Adults with Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: Hypercholesterolemia is a key modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Injectable PCSK9 inhibitors lower LDL-C effectively but are limited by cost and parenteral administration. Oral PCSK9 inhibitors have
Authors
- Syed Ibad Hussain (ORCID: https://orcid.org/0009-0007-4229-777X)
- Mohammad Amir (ORCID: https://orcid.org/0000-0003-3432-4217)
- Muhammad Burhan (ORCID: https://orcid.org/0009-0005-7034-5594)
- Amna Amir Jalal (ORCID: https://orcid.org/0009-0005-5835-9811)
- Muhammad Saad Khan (ORCID: https://orcid.org/0009-0002-4228-6476)
- Asra Karim (ORCID: https://orcid.org/0009-0000-5540-1352)
- Rabia Nizam
- Erum Siddiqui (ORCID: https://orcid.org/0009-0006-7183-1022)
Institutions
- Jinnah Sindh Medical University (PK)
- Dow University of Health Sciences (PK)
- Bahria University (PK)
Publication Details
- Published
- 2025-10-09
- DOI
- https://doi.org/10.22541/au.175999156.65770492/v1
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00